{"filing":{"accession_number":"0001171843-26-005729","cik":"0001421876","ticker":"GLPG","company_name":"Lakefront Biotherapeutics NV","form":"6-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"f6k_082526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1421876/000117184326005729/f6k_082526.htm"},"events":[{"id":29383,"run_id":26901,"accession_number":"0001171843-26-005729","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The press release announces that the U.S. FDA has granted Orphan Drug Designation to gamgertamig for treatment of pemphigus, a regulatory milestone for Lakefront's lead clinical-stage asset. This is a material operational/regulatory event that advances the company's development program and provides competitive advantages (orphan drug status), but it is not a discrete transaction (M\u0026A), financial obligation (debt), capital event (dilution), or personnel change. The designation is a significant clinical and regulatory achievement that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.","company_name":"Lakefront Biotherapeutics NV","ticker":"GLPG","filing_date":"2026-08-25","form":"6-K","submitted_at":null,"items":[{"id":31645,"accession_number":"0001171843-26-005729","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces that the U.S. FDA has granted Orphan Drug Designation to gamgertamig for treatment of pemphigus, a regulatory milestone for Lakefront's lead clinical-stage asset. This is a material operational/regulatory event that advances the company's development program and provides competitive advantages (orphan drug status), but it is not a discrete transaction (M\u0026A), financial obligation (debt), capital event (dilution), or personnel change. The designation is a significant clinical and regulatory achievement that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:30:04.339025+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31645,"accession_number":"0001171843-26-005729","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The press release announces that the U.S. FDA has granted Orphan Drug Designation to gamgertamig for treatment of pemphigus, a regulatory milestone for Lakefront's lead clinical-stage asset. This is a material operational/regulatory event that advances the company's development program and provides competitive advantages (orphan drug status), but it is not a discrete transaction (M\u0026A), financial obligation (debt), capital event (dilution), or personnel change. The designation is a significant clinical and regulatory achievement that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-25T14:30:04.339025+00:00","company_name":"Lakefront Biotherapeutics NV","ticker":"GLPG","filing_date":"2026-08-25"}]}